Your shopping cart is currently empty

RP-832c is a synthetic analog of a host defense peptide (HDP) that targets the mannose receptor CD206 on M2-polarized macrophages with a Kd of 3.5 μM. Upon binding to CD206, RP-832c induces significant conformational changes in the receptor, activating signaling pathways that lead to rapid apoptosis of CD206-positive M2 macrophages and their repolarization to the M1 phenotype. Treatment with RP-832c significantly reduces CD206 gene expression in M2 macrophages and temporarily increases the expression of the M1 macrophage marker TNF-α. RP-832c is applicable for research on T-cell lymphomas (CTCL) and idiopathic pulmonary fibrosis (IPF).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | RP-832c is a synthetic analog of a host defense peptide (HDP) that targets the mannose receptor CD206 on M2-polarized macrophages with a Kd of 3.5 μM. Upon binding to CD206, RP-832c induces significant conformational changes in the receptor, activating signaling pathways that lead to rapid apoptosis of CD206-positive M2 macrophages and their repolarization to the M1 phenotype. Treatment with RP-832c significantly reduces CD206 gene expression in M2 macrophages and temporarily increases the expression of the M1 macrophage marker TNF-α. RP-832c is applicable for research on T-cell lymphomas (CTCL) and idiopathic pulmonary fibrosis (IPF). |
| In vitro | RP-832c exhibits dose-dependent inhibition of M2-polarized bone marrow-derived macrophages (BMDM) within a concentration range of 0-100 μM, with an IC50 of 6.184 μM. It shows minimal cytotoxicity towards M1-polarized macrophages and no cytotoxicity to the human fetal lung fibroblast cell lines MRC5 and IMR9. At 10 μM for 24 hours, RP-832c significantly reduces CD206 expression in M2 macrophages and temporarily increases TNF-α expression. |
| In vivo | RP-832c, administered via intraperitoneal injection once daily for 10 days, inhibits tumor growth in the tumor microenvironment of cutaneous T-cell lymphoma by inducing the transition of immunosuppressive M2 macrophages to antitumor M1 macrophages. Additionally, RP-832c (5-10 mg/kg, subcutaneous injection, once daily for 21 days) demonstrates significant preventive and therapeutic effects in a mouse model of pulmonary fibrosis. |
| Molecular Weight | 1367.60 |
| Formula | C68H94N20O11 |
| Cas No. | 2375823-45-1 |
| Smiles | C([C@H](NC([C@@H](NC([C@H](CC1=CC=CC=C1)NC(CNC(CNC([C@H](CC2=CC=CC=C2)NC([C@@H](NC([C@H](CC=3C=4C(NC3)=CC=CC4)NC([C@H](CCCNC(=N)N)N)=O)=O)CCCCN)=O)=O)=O)=O)=O)CCCCN)=O)C(N[C@@H](CCCNC(=N)N)C(O)=O)=O)C=5C=6C(NC5)=CC=CC6 |
| Sequence | Arg-Trp-Lys-Phe-Gly-Gly-Phe-Lys-Trp-Arg |
| Sequence Short | RWKFGGFKWR |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.